OS Therapies Acquires Full IP Rights to OST-HER2 for $8M

Key Takeaways

• April 9, 2025 closing: OS Therapies paid an aggregate $8 million for Ayala’s Listeria immuno-oncology assets and IP, per the company’s Form 8-K.
• OST-HER2 IP is now owned outright; the package also includes ADXS-503 (Phase 2 lung) and ADXS-504 (Phase 1 prostate).
• Disclosures cite royalty reduction from 10% to 1.5% of net sales and removal of $16.5 million in early sales milestones.
• OST-HER2 remains investigational in humans; the Phase 2b osteosarcoma study is registered as NCT04974008.

What did the $8 million Ayala deal actually buy?

According to the April 9, 2025 Form 8-K, OS Therapies closed an Asset Purchase Agreement dated January 28, 2025 with Ayala Pharmaceuticals, Inc. (formerly Advaxis, Inc.). The company acquired Lm-based immuno-oncology programs and related intellectual property assets for an aggregate purchase price of $8,000,000, paid in cash and common stock consideration detailed in the filing.

Primary confirmation is in the SEC Form 8-K closing disclosure. Earlier agreement terms described about $0.5 million cash and $7.5 million in OS Therapies common shares, subject to the final consideration schedule in the 8-K.

Why did OS Therapies buy OST-HER2 IP now?

OST-HER2 (also called OST31-164) is a HER2-targeted Listeria monocytogenes immunotherapy. OS Therapies had previously licensed the program; buying the platform IP removes shared ownership friction ahead of a planned biologics license path in osteosarcoma.

In a February 2025 Business Wire corporate update, management said a core reason for the deal was to eliminate an expected near-term $3.5 million cash milestone due upon the earlier of FDA approval of OST-HER2 or initiation of a pivotal trial. The same update said the acquisition reduces the royalty rate from 10% to 1.5% of net sales and eliminates $16.5 million in milestones on the first $100 million in sales.

Which pipeline assets transferred with OST-HER2?

Beyond OST-HER2 IP consolidation, the purchased package includes two additional clinical candidates on the Listeria platform:

• ADXS-503: Phase 2 lung cancer program
• ADXS-504: Phase 1 prostate cancer program
• Related Listeria monocytogenes immuno-oncology intellectual property

Those assets broaden optionality but do not, by themselves, establish clinical proof for osteosarcoma approval. Capital allocation statements from the company still prioritize regulatory review, a potential priority review voucher, and commercialization planning for OST-HER2 in osteosarcoma.

What does the OST-HER2 osteosarcoma trial show so far?

The Phase 2 maintenance study after resection of recurrent pulmonary osteosarcoma is listed on ClinicalTrials.gov as NCT04974008 (OST-164-01 / OST31-164). The registry describes an open-label, multicenter, single-arm Phase 2 design in patients aged 12 to 39 years, with dosing every 3 weeks for 48 weeks and long-term survival follow-up.

Company-reported Phase 2b topline updates have claimed statistically significant 12-month event-free survival versus published historical controls and later overall-survival signals at interim timepoints. Those efficacy figures come from sponsor communications, not from an FDA approval decision, and should be treated as company-reported until regulators complete review.

How does the deal change economics for partners and buyers?

For BD and finance teams, the practical change is margin structure if OST-HER2 reaches the market. Cutting royalties from 10% to 1.5% and removing $16.5 million of early sales milestones improves early commercial cash flow relative to the prior license stack. The $8 million consideration mixes cash and equity, so dilution and share-count effects matter as much as the headline cash outlay.

Competitive read-through for osteosarcoma remains limited: the indication is rare, and no Listeria-based HER2 vaccine is yet an approved U.S. standard of care in this setting. Ownership consolidation reduces deal friction; it does not substitute for a Biologics License Application decision.

What remains unproven after the IP acquisition?

The April 2025 closing proves ownership and contract economics, not regulatory success. OST-HER2 has not received FDA marketing approval for osteosarcoma. Human efficacy claims still rest on a single-arm Phase 2 program (NCT04974008) versus historical controls, which regulators may weigh differently than a randomized confirmatory design.

Company timelines that mention a 2026 BLA or conditional authorizations abroad are forward-looking statements. ADXS-503 and ADXS-504 add pipeline breadth but lack late-stage, registrational proof in their respective indications as of the deal disclosures cited here.

Related NovaPharma coverage

• OS Therapies' OST-HER2 Trial Hits 2.5-Year Survival Milestone in Osteosarcoma
• OS Therapies' OST-HER2 Nears FDA Accelerated Approval for Osteosarcoma Amidst ASCO Data Presentation
• OS Therapies Publishes Four Articles on OST-HER2 and Osteosarcoma, Signaling Clinical Progress

Frequently Asked Questions

Primary Sources

1. SEC Form 8-K: April 9, 2025 Ayala asset purchase closing
2. Business Wire: OS Therapies corporate update on acquisition economics
3. ClinicalTrials.gov NCT04974008: OST31-164 osteosarcoma Phase 2 study